References
1
White AC, Thannickal VJ, Fanburg BL. Glutathione deficiency in human disease.
J Nutr Biochem. 1994;5:218–26.
2
Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione.
Eur J Clin Pharmacol. 1992;43:667–9.
3
Hunjan MK, Evered DF. Absorption of glutathione from the gastro-intestinal tract.
Biochim Biophys Acta. 1985;815:184–8.
4
Bounous G. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment.
Anticancer Res. 2000;20:4785-92.
5
Bounous G, Gervais F, Amer V, Batist G, Gold P. The influence of dietary whey protein on tissue glutathione and the diseases of aging.
Clin Invest Med. 1989;12:343–9.
6
Micke P, Beeh KM, Schlaak JF, Buhl R. Oral supplementation with whey proteins increases plasma glutathione levels of HIV-infected patients.
Eur J Clin Invest. 2001;31:171–8.
7
Watanabe A, Okada K, Shimizu Y, et al.
Nutritional therapy of chronic hepatitis by whey protein (non-heated).
J Med. 2000;31:283–302.
8
Henning SM, Zhang JZ, McKee RW, Swendseid ME, Jacob RA. Glutathione blood levels and other oxidant defense indices in men fed diets low in vitamin C.
J Nutr. 1991;121:1969–75.
9
Johnston CS, Meyer CG, Srilakshmi JC. Vitamin C elevates red blood cell glutathione in healthy adults.
Am J Clin Nutr. 1993;58:103–5.
10
Arivazhagan P, Ramanathan K, Panneerselvam C. Effect of DL-alpha-lipoic acid on glutathione metabolic enzymes in aged rats.
Exp Gerontol. 2001;37:81–7.
11
Bunin AIa, Filina AA, Erchev VP. A glutathione deficiency in open-angle glaucoma and the approaches to its correction.
Vestn Oftalmol. 1992;108:13–5.
12
Han D, Handelman G, Marcocci L, et al.
Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization.
Biofactors. 1997;6:321–38.
13
Hultberg B, Andersson A, Isaksson A. Lipoic acid increases glutathione production and enhances the effect of mercury in human cell lines.
Toxicology. 2002;175:103–10.
14
Packer L, Kraemer K, Rimbach G.
Molecular aspects of lipoic acid in the prevention of diabetes complications.
Nutrition. 2001;17:888–95.
15
Sen CK, Roy S, Han D, Packer L.
Regulation of cellular thiols in human lymphocytes by alpha-lipoic acid: a flow cytometric analysis.
Free Radic Biol Med. 1997;22:1241–57.
16
Droge W, Breitkreutz R. Glutathione and immune function.
Proc Nutr Soc. 2000;59:595–600.
17
De Rosa SC, Zaretsky MD, Dubs JG, et al.
N-acetylcysteine replenishes glutathione in HIV infection.
Eur J Clin Invest. 2000;30:915–29.
18
Witschi A, Junker E, Schranz C, Speck RF, Lauterburg BH. Supplementation of N-acetylcysteine fails to increase glutathione in lymphocytes and plasma of patients with AIDS.
AIDS Res Hum Retroviruses. 1995;11:141–3.
19
Droge W, Breitkreutz R. N-acetyl-cysteine in the therapy of HIV-positive patients.
Curr Opin Clin Nutr MetabCare. 1999;2:493–8.
20
Amores-Sanchez MI, Medina MA. Glutamine, as a precursor of glutathione, and oxidative stress.
Mol GenetMetab. 1999;67:100–5.
21
Wang ST, Chen HW, Sheen LY, Lii CK. Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes.
J Nutr. 1997;127:2135–41.
22
Vendemiale G, Altomare E, Trizio T, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease.
Scand J Gastroenterol.
1989;24:407–15.
23
Molloy J, Martin JF, Baskerville PA, et al. S-nitrosoglutathione reduces the rate of embolization in humans.
Circulation. 1998;98:1372–5.
24
Campbell KC, Larsen DL, Meech RP, Rybak LP, Hughes LF.
Glutathione ester but not glutathione protects against cisplatin-induced ototoxicity in a rat model.
J Am Acad Audiol. 2003;14:124–33.
25
Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.
Ann Oncol. 1997;8:569–73.
26
Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial.
J Clin Oncol. 1995;13:26–32.
27
Lenzi A, Picardo M, Gandini L, et al. Glutathione treatment of dyspermia: effect on the lipoperoxidation process.
Hum Reprod. 1994;9:2044–50.
28
Lenzi A, Culasso F, Gandini L, et al. Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility.
Hum Reprod. 1993;8:1657–62.
29
Lenzi A, Gandini L, Picardo M, Tramer F, Sandri G, Panfili E.
Lipoperoxidation damage of spermatozoa polyunsaturated fatty acids (PUFA): scavenger mechanisms and possible scavenger therapies.
Front Biosci. 2000 Jan 1;5:E1-E15.
30
Lenzi A, Gandini L, Picardo M. A rationale for glutathione therapy.
Hum Reprod. 1998;13:1419–22.
31
Lenzi A, Picardo M, Gandini L, Dondero F.
Lipids of the sperm plasma membrane: from polyunsaturated fatty acids considered as markers of sperm function to possible scavenger therapy.
Hum ReprodUpdate. 1996;2:246–56.
32
Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. Glutathione, iron and Parkinson's disease.
BiochemPharmacol. 2002;64:1037–48.
33
Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson’s disease.
Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:1159–70.